From a tanning drug to tests in women
PT-141 Research: What Each Study Can Show
You'll follow the work from animal clues, so you can judge the changes women reported.
How did the research begin?
A tanning-drug team first made PT-141. They wanted the sexual effect to last longer. The medicine that followed is bremelanotide.
PT-141 attaches to receptors, the receiving points on brain cells [1]. Those cells help guide sexual desire. The drug doesn't raise desire by opening blood vessels.
Animal studies came first and found sexual effects [1][2]. Researchers then ran two large human studies, which found a small average gain [3][4]. All the women were before menopause.
Brain scans and work from 2024-2025 added details [5][6]. Each numbered note leads to a study. You can check who or what was tested.
Start with the people or animals in each study. Then check how long the study ran. Those facts tell you how much trust to place in the result.
How does the drug send a brain message?
Your body makes hormones that carry messages [1]. PT-141 copies one of those hormones. It attaches to a receptor, the receiving point on a brain cell [1].
The brain cell may then send a message linked with desire [2]. Scientists don't know every step yet. Your own response may differ.
Sildenafil is a PDE-5 erection pill that relaxes blood-vessel muscle. That helps more blood reach the penis. PT-141 begins in the brain [1].
This brain action may cause nausea, blood pressure changes, and flushing, which means sudden warmth and red skin [7]. One drug may affect desire, while the other helps blood flow. Remember that split as you judge the drug.
What is the PT-141 peptide, a drug made from protein parts?
A peptide is a short chain. Seven amino acids make PT-141. Your body uses amino acids as the raw parts for proteins. The parts are linked into a ring [7].
Scientists measure molecule weight in units called daltons. The drug weighs about 1,025 daltons. That figure helps a lab confirm the drug, but it won't tell you what to expect.
Scientists reshaped a related tanning drug. Joining its ends into a ring helped it resist breakdown [7]. That change lets the drug stay whole longer.
After an under-skin shot, the amount in blood rises fast. It reaches its high point near one hour. Half leaves the blood in about 2.7 hours [7].
The ring breaks into small pieces inside you. Your kidneys remove most of those pieces [7]. Clearing from blood can't tell how long you'd notice an effect.
How much change did women report?
Two Phase 3 studies included 1,267 women. This was a large, late test in people. All the women were before menopause.
Women got 1.75 mg or a placebo, a dummy shot. After 24 weeks, women who got the drug reported a slight rise in desire [3]. Their distress about low desire eased slightly too.
The chance test was below .001 for desire and below .001 for distress. That tells you the differences were unlikely to be luck, not that the gains were large. The study didn't give a simple count of women who felt enough change to matter.
Women most often had nausea, headache, or flushing, which means sudden warmth and red skin [3]. You'd weigh those harms against the small average gain. Your result might not match that average.
Next, 684 women stayed in a 52-week study. The gain held, and no new harm appeared. Nausea (40.4%), flushing (20.6%), and headache (12.0%) stayed common [4].
What did brain scans and newer studies add?
In 2022, researchers scanned 31 women before menopause. They reported higher desire for as many as 24 hours [5]. They viewed sexual pictures during the scans.
Two brain areas that help judge feelings worked more closely. That finding shows a brain response. Even so, it can't show whether every woman would notice a useful change.
In 2025, female hamsters didn't find mating more rewarding [6]. That's an animal finding, not a human one. You can't use it to predict your response.
In 2024, brain-cancer cells grew more slowly in a dish [13]. No person received cancer care in that study. In 2025, reviewers said the drug may help some women, but its average benefit remains small [16].
These studies asked very different questions. You can't mix results from women, animals, and cells in a dish. Keeping them apart stops an early clue from sounding like proof.